Key Features
Enhance your research with our curated data sets and powerful platform features. Pluto Bio makes it simple to find and use the data you need.
Learn More
PLX301546
GSE140077: Transcriptome analysis of human pancreatic cancer cell lines and gemcitabine-resistant pancreatic cancer cell lines
- Organsim mouse
- Type RNASEQ
- Target gene
- Project ARCHS4
Gemcitabine (GEM) alone and GEM-based chemotherapy are the preferred regimens for treating advanced unresectable and metastatic pancreatic cancer (PC). However, these treatments have limited efficacy due to acquired resistance of cancer cells to chemotherapy, the mechanisms of which are not fully understood. In this study, we established two GEM-resistant cell lines (BxPC-3-GR and CFPAC-1-GR) and compared the expression profiles of mRNAs between parental (BxPC-3 and CFPAC-1) and GEM-resistant cells by high-throughput RNA sequencing, and to identify potential targets for GEM response in PC patients. SOURCE: Jiarong Zhou (zhoujiarong@zju.edu.cn) - Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province The Second Affiliated Hospital, Zhejiang University School of Medicine
View on GEOView in PlutoAnalyze and visualize data for this experiment
Use Pluto's intuitive interface to analyze and visualize data for this experiment. Pluto's platform is equipped with an API & SDKs, making it easy to integrate into your internal bioinformatics processes.
Read about post-pipeline analysisView QC data and experiment metadata
View quality control data and experiment metadata for this experiment.
Request import of other GEO data
Request imports from GEO or TCGA directly within Pluto Bio.
Chat with our Scientific Insights team